16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome. (July 2021)

• Record Type: Journal Article
• Authors: Sciascia, Savino; Radin, Massimo; Cecchi, Irene; Levy, Roger A; Erkan, Doruk
• Is Part Of: Lupus. Volume 30:Number 8(2021)
• Page Start: 1314
• Page End: 1326
• Publication Date: 2021-07
• Subjects: Antiphospholipid syndrome -- antiphospholipid antibodies -- task force, thrombosis -- risk stratification; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1177/09612033211020361
• Languages: English
• ISSNs: 0961-2033

Abstract

The objectives of the 16th International Congress on Antiphospholipid Antibodies (aPL) Task Force on Clinical Manifestations of Antiphospholipid Syndrome (APS) were to critically analyze: a) the definition of "APS"; b) the current knowledge on non-traditional manifestations associated with aPL; and c) the risk stratification strategies in aPL-positive patients. The quality of evidence was assessed by the GRADE system. The task force concluded that: a) APS does not have a uniform definition given the heterogeneity of the clinical presentations and different aPL profiles; b) current literature supports the role for aPL testing in cases of thrombocytopenia and recurrent cardiac events but are limited by vast heterogeneity, providing an overall low-to-very low level of evidence; and c) risk stratification strategies in aPL-positive patients, such as aPL-Score and Global APS Score, can be useful in clinical practice. International multicenter studies are still highly needed to improve the quality of available evidence and consequently the strength of future recommendations.